MedTrace Logo

Medical Food for the Dietary Management of Metastatic Colorectal Cancer

NCT05183295 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-04-03

No results posted yet for this study

Summary

This is a single arm study evaluating the tolerability and markers of colorectal cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic colorectal cancer. Subjects will be receiving two FDA approved second line drug therapies, fluoropyrimidine and oxaliplatin ± bevacizumab (FOLFIRI + BEV) that are routinely prescribed in combination for metastatic colorectal cancer as part of their routine care.

Conditions

Interventions

OTHER

NEAAR Medical Food

Standardized non-essential amino acid restricted medical food

Sponsors & Collaborators

  • Faeth Therapeutics

    lead INDUSTRY

Principal Investigators

  • Andrea Cerceck, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-27
Primary Completion
2023-03-27
Completion
2023-03-27

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05183295 on ClinicalTrials.gov